Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Molecular Oncology
|
June 16, 2026
Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, et al.
Molecular Oncology
|
February 19, 2022
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
Pauline A J Mendelaar, Debbie G J Robbrecht, Maud Rijnders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells
Maud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors
Ignacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Hanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
BJC Reports
|
November 8, 2024
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study
Chantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, et al.
Nature Communications
|
February 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
Maud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Nature Medicine
|
February 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
Jan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Molecular Oncology
|
June 16, 2026
Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, et al.
Molecular Oncology
|
February 19, 2022
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
Pauline A J Mendelaar, Debbie G J Robbrecht, Maud Rijnders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells
Maud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors
Ignacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
Hanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
BJC Reports
|
November 8, 2024
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study
Chantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, et al.
Nature Communications
|
February 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
Maud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Nature Medicine
|
February 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
Jan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts, et al.
Page
of 3